Autofluorescence imaging resolves early cancer treatment response in vivo

Alex Walsh; Rebecca S. Cook; H. Charles Manning; Donna J. Hicks; Alec Lafontant; Carlos L. Arteaga; Melissa C. Skala

doi:10.1364/omp.2013.mt3c.5

Autofluorescence imaging resolves early cancer treatment response in vivo

Alex Walsh, Rebecca S. Cook, H. Charles Manning, Donna J. Hicks, Alec Lafontant, Carlos L. Arteaga, Melissa C. Skala

Research output: Chapter in Book/Report/Conference proceeding › Conference contribution

Abstract

NADH and FAD auto-fluorescence intensity and lifetime imaging are used to monitor breast cancer metabolism. In vivo imaging of xenograft tumors revealed metabolic differences in responsive but not resistant tumors treated with trastuzumab at earlier time points than FDG-PET.

Original language	English (US)
Title of host publication	Optical Molecular Probes, Imaging and Drug Delivery, OMP 2013
Publisher	Optical Society of America (OSA)
Pages	MT3C.5
ISBN (Print)	9781557529664
DOIs	https://doi.org/10.1364/omp.2013.mt3c.5
State	Published - 2013
Event	Optical Molecular Probes, Imaging and Drug Delivery, OMP 2013 - Waikoloa Beach, HI, United States Duration: Apr 14 2013 → Apr 18 2013

Publication series

Name	Optical Molecular Probes, Imaging and Drug Delivery, OMP 2013

Other

Other	Optical Molecular Probes, Imaging and Drug Delivery, OMP 2013
Country/Territory	United States
City	Waikoloa Beach, HI
Period	4/14/13 → 4/18/13

ASJC Scopus subject areas

Radiology Nuclear Medicine and imaging
Atomic and Molecular Physics, and Optics

Access to Document

10.1364/omp.2013.mt3c.5

Cite this

Walsh, A., Cook, R. S., Manning, H. C., Hicks, D. J., Lafontant, A., Arteaga, C. L., & Skala, M. C. (2013). Autofluorescence imaging resolves early cancer treatment response in vivo. In Optical Molecular Probes, Imaging and Drug Delivery, OMP 2013 (pp. MT3C.5). (Optical Molecular Probes, Imaging and Drug Delivery, OMP 2013). Optical Society of America (OSA). https://doi.org/10.1364/omp.2013.mt3c.5

Autofluorescence imaging resolves early cancer treatment response in vivo. / Walsh, Alex; Cook, Rebecca S.; Manning, H. Charles et al.
Optical Molecular Probes, Imaging and Drug Delivery, OMP 2013. Optical Society of America (OSA), 2013. p. MT3C.5 (Optical Molecular Probes, Imaging and Drug Delivery, OMP 2013).

Research output: Chapter in Book/Report/Conference proceeding › Conference contribution

Walsh, A, Cook, RS, Manning, HC, Hicks, DJ, Lafontant, A, Arteaga, CL & Skala, MC 2013, Autofluorescence imaging resolves early cancer treatment response in vivo. in Optical Molecular Probes, Imaging and Drug Delivery, OMP 2013. Optical Molecular Probes, Imaging and Drug Delivery, OMP 2013, Optical Society of America (OSA), pp. MT3C.5, Optical Molecular Probes, Imaging and Drug Delivery, OMP 2013, Waikoloa Beach, HI, United States, 4/14/13. https://doi.org/10.1364/omp.2013.mt3c.5

@inproceedings{587997d1451642818fbaefd2798449c2,

title = "Autofluorescence imaging resolves early cancer treatment response in vivo",

abstract = "NADH and FAD auto-fluorescence intensity and lifetime imaging are used to monitor breast cancer metabolism. In vivo imaging of xenograft tumors revealed metabolic differences in responsive but not resistant tumors treated with trastuzumab at earlier time points than FDG-PET.",

author = "Alex Walsh and Cook, {Rebecca S.} and Manning, {H. Charles} and Hicks, {Donna J.} and Alec Lafontant and Arteaga, {Carlos L.} and Skala, {Melissa C.}",

year = "2013",

doi = "10.1364/omp.2013.mt3c.5",

language = "English (US)",

isbn = "9781557529664",

series = "Optical Molecular Probes, Imaging and Drug Delivery, OMP 2013",

publisher = "Optical Society of America (OSA)",

pages = "MT3C.5",

booktitle = "Optical Molecular Probes, Imaging and Drug Delivery, OMP 2013",

}

TY - GEN

T1 - Autofluorescence imaging resolves early cancer treatment response in vivo

AU - Walsh, Alex

AU - Cook, Rebecca S.

AU - Manning, H. Charles

AU - Hicks, Donna J.

AU - Lafontant, Alec

AU - Arteaga, Carlos L.

AU - Skala, Melissa C.

PY - 2013

Y1 - 2013

N2 - NADH and FAD auto-fluorescence intensity and lifetime imaging are used to monitor breast cancer metabolism. In vivo imaging of xenograft tumors revealed metabolic differences in responsive but not resistant tumors treated with trastuzumab at earlier time points than FDG-PET.

AB - NADH and FAD auto-fluorescence intensity and lifetime imaging are used to monitor breast cancer metabolism. In vivo imaging of xenograft tumors revealed metabolic differences in responsive but not resistant tumors treated with trastuzumab at earlier time points than FDG-PET.

UR - http://www.scopus.com/inward/record.url?scp=84887538934&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887538934&partnerID=8YFLogxK

U2 - 10.1364/omp.2013.mt3c.5

DO - 10.1364/omp.2013.mt3c.5

M3 - Conference contribution

AN - SCOPUS:84887538934

SN - 9781557529664

T3 - Optical Molecular Probes, Imaging and Drug Delivery, OMP 2013

SP - MT3C.5

BT - Optical Molecular Probes, Imaging and Drug Delivery, OMP 2013

PB - Optical Society of America (OSA)

T2 - Optical Molecular Probes, Imaging and Drug Delivery, OMP 2013

Y2 - 14 April 2013 through 18 April 2013

ER -

Autofluorescence imaging resolves early cancer treatment response in vivo

Abstract

Publication series

Other

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this